Article Text

PDF
Randomised controlled trial
Antiretroviral combination therapy markedly reduces risk of heterosexual HIV-1 transmission
  1. Mathias Lichterfeld1,
  2. Eric S Rosenberg2
  1. 1Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
  2. 2Department of Medicine and Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
  1. Correspondence to Eric S Rosenberg
    Department of Medicine and Pathology, Massachusetts General Hospital, Gray J-504, 55 Fruit Street, Boston, MA 02114, USA; erosenberg1{at}partners.org

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

The reduction of HIV-1 transmission remains one of the highest global health priorities. The use of established antiretroviral drugs for preventing HIV-1 transmission was first considered in 1994, after an observational clinical study showed reduced HIV-1 infection rates in partners of HIV-1 infected persons treated with zidovudine monotherapy.1 In 2007, the HIV Prevention Trials Network (HPTN) initiated a randomised-controlled clinical trial (HPTN 052) in which the effect of antiretroviral combination therapy on heterosexual transmission of HIV-1 was evaluated; the results have recently been reported.

Methods

HPTN 052 is a phase III, randomised-controlled clinical trial designed to determine if early initiation of antiretroviral therapy could reduce transmission of HIV-1 in …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.